Biofield Energy Therapy: Role in Multiple Organ Health Specific Biomarkers in Cell-Based Assay

Journal: Annals of Advanced Biomedical Sciences PDF  

Published: July 16, 2019 Volume: 2 Issue: 5

ISSN: 2641-9459

Authors: Sakina Aleemah Ansari, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Mayank Gangwar and Snehasis Jana

Citation: Sakina Aleemah Ansari, et al. Biofield Energy Therapy: Role in Multiple Organ Health Specific Biomarkers in Cell-Based Assay. Ann Adv Biomed Sci 2019, 2(5): 000136.

  • 127 Views
  • 1 Downloads

Abstract

The major cause of high rate of mortality is the multiple organ dysfunction among critical care healthcare services. The aim of the current study was to evaluate the impact of the Biofield Energy Treated test formulation using standard and specific cell lines related with vital organs functioning. The test formulation and the specific cell media was divided into two parts; one part was untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Sakina Aleemah Ansari, USA and labeled as the Biofield Energy Treated (BT) test formulation/media. The test formulation was tested against various activities using cell line assay in their specific medium (Med). The test formulation was tested for cell viability, and the results showed that the test formulation at tested concentrations was found safe and non-toxic. Cytoprotective activity showed improved cellular restoration by 105.4% (at 25 µg/mL), 32.8% (at 25 µg/mL), and 151.8% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BTMed + BT-TI groups respectively, as compared to the untreated test group in the human cardiac fibroblasts cells (HCF) cells, while improved restoration of cell viability by 22.4% (at 25.5 µg/mL), 67.1% (at 10 µg/mL), and 72.9% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group in HepG2 cells. Cellular restoration in A549 cells was improved by 9.3%, 70.4%, and 14.1% at 0.1, 1, and 25.5 µg/mL respectively, in the BT-Med + UT-TI group, while 3% and 4.6% improved cellular restoration was reported at 10 and 25.5 µg/mL respectively, at BT-Med + BT-TI groups as compared to the untreated test group. ALP activity in Ishikawa cells was significantly increased by 68.4%, 41.1%, and 18.8% at 0.1, 10, and 50 µg/mL respectively, in the UT-Med + BTTI group, while in MG-63 cells showed maximum increased ALP activity by 92.7%, 84.5%, and 93.2% respectively in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI group respectively, at 50 µg/mL as compared to the untreated group. The maximum percent cellular protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 51.6%, 88.7%, and 53.7% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, at 10 µg/mL as compared to the untreated group. Alanine amino transferase (ALT) activity was reported in terms of percent cellular protection of HepG2 (liver) cells. The test data showed improved HepG2 cells protection (represents decreased ALT activity) by 33%, 90.2%, and 72.1% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, at 25 µg/mL as compared to the untreated test group. Percentage cellular protection of A549 (lungs) cells (represents increased of SOD activity) was increased by 21.5% at 25.5 µg/mL in the UT-Med + BT-TI, while 33.4%, 25.8%, and 21.5% at 1, 10, and 25.5 µg/mL respectively, in the BT-Med + UT-TI group, and 12.8% increased SOD activity at 25.5 µg/mL in the BT-Med + BT-TI groups as compared to the untreated group. Serotonin level was significantly increased 137.4% (at 0.1 µg/mL), 65.4% (at 0.1 µg/mL), and 77.3% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UTTI, and BT-Med + BT-TI groups, respectively compared to untreated test group in human neuroblastoma cells (SH-SY5Y). However, the relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 24.2% (at 1 µg/mL), 213.7% (at 10 µg/mL), and 328.7% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. Thus, the data concluded that The Trivedi Effect® would be significantly useful for improving multiple organs health, which can be used for many coronary artery diseases, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc

Conclusion

MTT assay was used for estimation of safe concentrations of the test formulation and results showed that the test formulation was found safe and non-toxic against all the tested cell lines. Cytoprotective activity against t-BHP induced cell damage was tested using human cardiac fibroblasts cells (HCF), which showed restoration of cell viability by 105.4% (at 25 µg/mL), 32.8% (at 25 µg/mL), and 151.8% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group, while in HepG2 cells the maximum restoration of cell viability was by 22.4% (at 25.5 µg/mL), 67.1% (at 10 µg/mL), and 72.9% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group. In A549 cells, cellular restoration was improved by 70.4%, and 14.1% at 1 and 25.5 µg/mL respectively, in the BT-Med + UT-TI group, while 3% and 4.6% improved cellular restoration was reported at 10 and 25.5 µg/mL respectively, at BTMed + BT-TI groups as compared to the untreated test group. Similarly, ALP activity in Ishikawa cells showed significantly increased ALP activity by 68.4%, 9.6%, and 12.3% in the UT-Med + BT-TI, BT-Med + UT-TI group, and BT-Med + BT-TI groups respectively, at 0.1 µg/mL as compared to the untreated test group. Similarly, ALP activity in MG-63 cells with maximum cellular protection was reported at 50 µg/mL by 92.7%, 84.5%, and 93.2% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BTTI group test groups, respectively, as compared with the untreated test group. LDH activity was significantly decreased and the data was presented in increased percentage cellular protection data, which showed maximum cellular protection at 10 µg/mL concentration by 51.6%, 88.7%, and 53.7% in the UT-Med + BT-TI, BTMed + UT-TI group, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. ALT activity showed maximum improved cellular protection of HepG2 cells (decreased of ALT activity) by 33%, 90.2%, and 72.1% at 25.5 µg/mL in the UT-Med + BT-TI, BT-Med + UT-TI group, and BT-Med + BT-TI groups respectively, as compared with the untreated test group. SOD activity was significantly increased by 21.5% (at 25.5 µg/mL), 33.4% (at 1 µg/mL), and 12.8% (at 25.5 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI group, and BTMed + BT-TI groups respectively, as compared with the untreated test group. Serotonin level was significantly increased in SH-SY5Y cells by 137.4% (at 0.1 µg/mL), 65.4% (at 0.1 µg/mL), and 77.3% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared with the untreated test group. VDR expression was tested in MG-63 cells, which showed increased RQ of VDR by 24.2% at 1 µg/mL in the UT-Med + BT-TI group, while 64.9%, 213.7%, and 127% increased RQ of VDR at 1, 10, and 50 µg/mL respectively in the BT-Med + UT-TI group, and 166.6%, 328.7%, and 205.1% increased RQ of VDR at 1, 10 and 50 µg/mL respectively, in the BT-Med + BT-TI groups as compared to the untreated test control group. Thus, it can be concluded that Biofield Energy Treatment (The Trivedi Effect®) can be used for the prevention of various types of cardiac disorders such as stroke, thromboembolic disease, congestive heart failure, congenital heart disease, peripheral artery disease, rheumatic heart disease, valvular heart disease, and venous thrombosis, etc. Biofield Energy based test formulation can improve the overall functioning of heart, liver, bones, neuronal, and lungs parameters against wide range of oxidative stress or damage induced by free radicals. In addition, it would also protect against many hepatic disorders (cirrhosis, liver cancer, hemochromatosis, and Wilson disease), lungs disorders (asthma, chronic bronchitis, emphysema, cystic fibrosis, and pneumonia), and many immune disorders. In addition, this novel test formulation can also be utilized for organ transplants (i.e., kidney, liver, and heart transplants), hormonal imbalance, aging, and various inflammatory and immune-related disease conditions like Asthma, Aplastic Anemia, Graves’ Disease, Dermatitis, Diabetes, Parkinson’s Disease, Myasthenia Gravis, Ulcerative Colitis (UC), Atherosclerosis, etc. to improve overall health and Quality of Life.